There is a tremendous amount of mechanistic overlap between targeted cancer therapy and cardiovascular tissues. Important drugs that may be active on cancerous tissues are increasingly likely to have significant collateral effects on cardiac tissues. Understanding the underlying mechanisms, and how to detect these problems early and manage them effectively, can allow a critical drug for cancer efficacy to continue to develop as a clinical therapy. Additionally, tailoring the pharmacology of a potential cancer therapeutic based on known mechanistic insights is an essential area of preclinical development. Furthermore, enhancing interactions between cardiology and oncology at all levels of clinical trials allows for optimal patient outcomes.
- Organization: DIA Europe
- Joint DIA/ICOS Conference on Cardiac Toxicity
Thu, Oct 09, 2014 - Fri, Oct 10, 2014
Dorint Hotel Don Giovanni
Vinohradska 2733/157a, Prague, 13020, Czech Republic
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.